(Q78061400)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

title

A phase II trial of irinotecan in hormone-refractory prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

main subject

phase II clinical trial

1 reference

1 reference

1 reference

D M Reese

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

S Tchekmedyian

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Y Chapman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

D Prager

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

P J Rosen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

10 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

353-359

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10426671%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1006120910380

10 December 2019

exact match

0 references

cites work

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer

1 reference

12 December 2020

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

12 December 2020

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

12 December 2020

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

12 December 2020

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer

1 reference

12 December 2020

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

12 December 2020

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer

1 reference

12 December 2020

Phase II study of topotecan in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

12 December 2020

Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020

Management of progressive metastatic prostate cancer.

1 reference

12 December 2020

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin

1 reference

12 December 2020

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

12 December 2020

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer

1 reference

12 December 2020

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo

1 reference

12 December 2020

Estramustine Phosphate Sodium

1 reference

12 December 2020